OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hamid on the Evolution of Precision Medicine in Prostate Cancer

April 3rd 2020

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

Dr. Kalinksy on pCR as a Surrogate Marker for EFS in TNBC

April 3rd 2020

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the use of pathologic complete response (pCR) rate as a surrogate marker for event-free survival (EFS) in triple-negative breast cancer (TNBC).

Dr. Jain on Treatment Options for Patients With Myelofibrosis Who Progress After Transplant

April 3rd 2020

Tania Jain, MBBS, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant.

Dr. Braunstein on Transplant Eligibility in Multiple Myeloma

April 3rd 2020

Marc J. Braunstein, MD, PhD, discusses transplant eligibility in multiple myeloma.

Dr. Iyer on Challenges With Selecting Patients With Bladder Cancer for FGFR Inhibitors

April 3rd 2020

Gopa Iyer, MD, discusses the challenges faced with identifying an optimal screening methodology to select patients with bladder cancer for FGFR inhibitor therapy.

Dr. Mehrazin on Findings From the CARMENA Trial in Metastatic RCC

April 3rd 2020

Reza Mehrazin, MD, discusses the findings of the phase III CARMENA trial in metastatic renal-cell carcinoma.

Dr. Moore on Early-Phase Data With Mirvetuximab Soravtansine in Ovarian Cancer

April 3rd 2020

Kathleen Moore, MD, discusses the early phase data that led to the development of the phase III FORWARD I/ GOG 3011 trial in ovarian cancer.

Dr. Choi on Impact of Frontline Treatment Decisions on Relapsed/Refractory CLL

April 3rd 2020

Michael Choi, MD, discusses how up-front treatment decisions impact what options can be given in the relapsed/refractory setting for patients with chronic lymphocytic leukemia.

Dr. Lin on CNS Activity With HER2-Directed TKIs in HER2+ Breast Cancer

April 2nd 2020

Nancy U. Lin, MD, discusses central nervous system activity with HER2-directed TKIs in HER2-positive breast cancer.

Dr. Miklos on the Safety Profile of KTE-X19 in MCL

April 2nd 2020

David Miklos, MD, discusses the safety profile of KTE-X19 in mantle cell lymphoma.

Dr. Park on Ongoing Research Efforts With CAR T-Cell Therapies in ALL

April 2nd 2020

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Dr. Lynce on Remaining Questions With PARP Inhibitors in Breast Cancer

April 2nd 2020

Filipa Lynce, MD, discusses remaining questions regarding the use of PARP inhibitors in breast cancer.

Oncologists Share How COVID-19 is Impacting Patients With Cancer

April 2nd 2020

OncLive interviewed experts at the State of the Science Summits™ in March 2020 on the impact of the COVID-19 pandemic on cancer care and shared what advice they have been giving their patients.

Dr. Awan on Novel Strategies Under Exploration in Relapsed/Refractory CLL

April 2nd 2020

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.

Dr. Bertino on Frontline Dacomitinib in Metastatic EGFR+ NSCLC

April 2nd 2020

Erin M. Bertino, MD, discusses the use of dacomitinib (Vizimpro) in the treatment of patients with non–small cell lung cancer with EGFR mutations and its place among other available EGFR TKIs.

Dr. Brown on Germline and Somatic Testing in Ovarian Cancer

April 2nd 2020

Jubilee Brown, MD, discusses germline and somatic testing in ovarian cancer.

Dr. Bakouny on the Utility of Checkpoint Inhibitors in Sarcomatoid RCC

April 2nd 2020

Ziad Bakouny, MD, MSc, discusses the utility of checkpoint inhibitors in renal cell carcinoma with sarcomatoid differentiation.

Dr. Kaseb on Research With Targeted Therapy in HCC

April 2nd 2020

Ahmed O. Kaseb, MD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses research with targeted therapy in hepatocellular carcinoma (HCC).

Dr. Bertino on the Impact of COVID-19 on Patients With Lung Cancer

April 2nd 2020

Erin M. Bertino, MD, a medical oncologist at The Ohio State University Comprehensive Cancer Center–James, discusses the potential impact of the novel coronavirus 2019 (COVID-19) on patients with lung cancer.

Dr. Raghav on Ongoing Research With Immunotherapy and Targeted Therapy in CRC

April 2nd 2020

Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy and targeted therapy in colorectal cancer (CRC).